Carrie Fijal, MSN, AGPCNP-BC, OCN

Current Trials

• Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma

  HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028

  Recruiting Participants

  Lymphoma

• Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

  HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033

  Recruiting Participants

  Prostate Cancer

• A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

  HIC ID2000031441RoleSub InvestigatorPrimary Completion Date09/01/2025

  Recruiting Participants

  Phase 1 Cancers

• Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients With Advanced Solid Tumors (MYTHIC Study)

  HIC ID2000030618RoleSub InvestigatorPrimary Completion Date10/30/2023

  Recruiting Participants

  Phase 1 Cancers

• Phase I, First-in-human, Open-label, Dose Escalation Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of BNT152+153 in Patients With Solid Tumors

  HIC ID2000030206RoleSub InvestigatorPrimary Completion Date09/01/2025

  Recruiting Participants

  Phase 1 Cancers